MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

SpringWorks Therapeutics Inc

Closed

SectorHealthcare

46.51 11.53

Overview

Share price change

24h

Current

Min

41.08

Max

46.89

Key metrics

By Trading Economics

Income

-24M

-77M

Sales

12M

62M

EPS

-1.04

Profit margin

-125.586

Employees

368

EBITDA

-23M

-80M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+71.23% upside

Dividends

By Dow Jones

Next Earnings

1 maj 2025

Market Stats

By TradingEconomics

Market Cap

-839M

3.3B

Previous open

34.98

Previous close

46.51

News Sentiment

By Acuity

50%

50%

180 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

SpringWorks Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2025, 07:03 UTC

Acquisitions, Mergers, Takeovers

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 lut 2025, 16:38 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

11 lut 2025, 10:54 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 lut 2025, 10:52 UTC

Market Talk
Acquisitions, Mergers, Takeovers

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Peer Comparison

Price change

SpringWorks Therapeutics Inc Forecast

Price Target

By TipRanks

71.23% upside

12 Months Forecast

Average 71.71 USD  71.23%

High 87 USD

Low 63 USD

Based on 7 Wall Street analysts offering 12 month price targets forSpringWorks Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

44.13 / 47.505Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.